肝细胞癌(hepatocellular carcinoma,HCC)是全球最常见的恶性肿瘤之一。近年来发现程序性死亡因子1及其受体(programmed cell death-1 and its ligand,PD-1/PD-L1)与HCC的产生和发展密切相关,为免疫治疗提供了一个新方向。然而,抗PD-1/P...肝细胞癌(hepatocellular carcinoma,HCC)是全球最常见的恶性肿瘤之一。近年来发现程序性死亡因子1及其受体(programmed cell death-1 and its ligand,PD-1/PD-L1)与HCC的产生和发展密切相关,为免疫治疗提供了一个新方向。然而,抗PD-1/PD-L1免疫治疗缺乏有效的生物标志物。最新研究发现,三级淋巴结构(tertiary lymphoid structures,TLS)对HCC的抗PD-1/PD-L1免疫治疗效果有一定的预测价值。本文对TLS和PD-1/PD-L1信号通路的发生过程,以及二者在肝细胞癌中的表达和临床中的具体研究进展作一综述,以期为TLS和PD-1/PD-L1信号通路在肝细胞癌中的应用前景提供新的参考。展开更多
Dear Editor,Mayer-Rokitansky-Küster-Hauser(MRKH)syndrome is a rare congenital disease characterized by the hypoplastic uterus and vagina in women with a normal female karyotype(46,XX)and phenotype.Although some g...Dear Editor,Mayer-Rokitansky-Küster-Hauser(MRKH)syndrome is a rare congenital disease characterized by the hypoplastic uterus and vagina in women with a normal female karyotype(46,XX)and phenotype.Although some genes and mutations,such as WNT4.展开更多
文摘肝细胞癌(hepatocellular carcinoma,HCC)是全球最常见的恶性肿瘤之一。近年来发现程序性死亡因子1及其受体(programmed cell death-1 and its ligand,PD-1/PD-L1)与HCC的产生和发展密切相关,为免疫治疗提供了一个新方向。然而,抗PD-1/PD-L1免疫治疗缺乏有效的生物标志物。最新研究发现,三级淋巴结构(tertiary lymphoid structures,TLS)对HCC的抗PD-1/PD-L1免疫治疗效果有一定的预测价值。本文对TLS和PD-1/PD-L1信号通路的发生过程,以及二者在肝细胞癌中的表达和临床中的具体研究进展作一综述,以期为TLS和PD-1/PD-L1信号通路在肝细胞癌中的应用前景提供新的参考。
基金supported by the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(2020PT320-003,2021-PT320-001)the National Natural Science Foundation of China(81830043)。
文摘Dear Editor,Mayer-Rokitansky-Küster-Hauser(MRKH)syndrome is a rare congenital disease characterized by the hypoplastic uterus and vagina in women with a normal female karyotype(46,XX)and phenotype.Although some genes and mutations,such as WNT4.
